Research programme: carbohydrate-based vaccines - Ancora

Drug Profile

Research programme: carbohydrate-based vaccines - Ancora

Latest Information Update: 30 Nov 2013

Price : $50

At a glance

  • Originator Ancora Pharmaceuticals
  • Class Carbohydrates; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Malaria; Staphylococcal infections

Most Recent Events

  • 07 Dec 2010 Preclinical trials in Staphylococcal infections (Prevention) in USA (unspecified route)
  • 07 Dec 2010 Ancora Pharmaceuticals receives federal grant from US Government under the Qualifying Therapeutic Discovery Program for vaccine development in Malaria (prevention)
  • 27 Oct 2005 Preclinical trials in Malaria (Prevention) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top